Journal ArticleDOI
Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.
Hugh A. Sampson,Anne Muñoz-Furlong,Ronna L. Campbell,N. Franklin Adkinson,S. Allan Bock,Amy M. Branum,Simon G A Brown,Carlos A. Camargo,Rita K. Cydulka,Stephen J. Galli,Jane Gidudu,Rebecca S. Gruchalla,Allen D. Harlor,David L. Hepner,Lawrence M. Lewis,Phillip Lieberman,Dean D. Metcalfe,Robert E. O'Connor,Antonella Muraro,Amanda Rudman,Cara Schmitt,Debra Scherrer,F. Estelle R. Simons,Stephen Thomas,Joseph P. Wood,Wyatt W. Decker +25 more
Reads0
Chats0
TLDR
There is no universal agreement on the definition of anaphylaxis or the criteria for diagnosis, so representatives from 16 different organizations or government bodies, including representatives from North America, Europe, and Australia, to continue working toward a universally accepted definition.Abstract:
There is no universal agreement on the definition of anaphylaxis or the criteria for diagnosis. In July 2005, the National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network convened a second meeting on anaphylaxis, which included representatives from 16 different organizations or government bodies, including representatives from North America, Europe, and Australia, to continue working toward a universally accepted definition of anaphylaxis, establish clinical criteria that would accurately identify cases of anaphylaxis with high precision, further review the evidence on the most appropriate management of anaphylaxis, and outline the research needs in this area.read more
Citations
More filters
Journal ArticleDOI
The etiology and incidence of anaphylaxis in Rochester, Minnesota: A report from the Rochester Epidemiology Project
Wyatt W. Decker,Ronna L. Campbell,Veena Manivannan,Anuradha Luke,Jennifer L. St. Sauver,Amy L. Weaver,M. Fernanda Bellolio,Eric J. Bergstralh,Latha G. Stead,James T. Li +9 more
TL;DR: The overall incidence rate of anaphylaxis is 49.8 per 100,000 person-years, which is higher than previously reported and the annual incidence rate is also increasing.
Journal ArticleDOI
Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005
TL;DR: Hospitalization rates for allergic conditions are on the increase, but the nature and causative factors differ between adults and children, and the relation of these changes to those in the prevalence of specific allergen sensitization in the community requires further investigation in population studies.
Journal ArticleDOI
Basophils Play a Pivotal Role in Immunoglobulin-G-Mediated but Not Immunoglobulin-E-Mediated Systemic Anaphylaxis
Yusuke Tsujimura,Kazushige Obata,Kaori Mukai,Hideo Shindou,Masayuki Yoshida,Hideto Nishikado,Yohei Kawano,Yoshiyuki Minegishi,Takao Shimizu,Hajime Karasuyama +9 more
TL;DR: It is shown that basophils, the least common blood cells, were dispensable for IgE-mediated anaphylaxis but played a critical role in IgG-mediated, passive and active systemic anaphYLaxis in mice, and two major, distinct pathways leading to allergen-induced systemic anphylaxis are contrasted.
Journal ArticleDOI
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal,David Kallend,Kausik K. Ray,Traci Turner,Wolfgang Koenig,Wolfgang Koenig,R. Scott Wright,Peter L.J. Wijngaard,Danielle Curcio,Mark Jaros,Lawrence A. Leiter,John J.P. Kastelein +11 more
TL;DR: Those who received inclisiran had significantly lower levels of LDL cholesterol than those who received placebo, with an infrequent dosing regimen and an acceptable safety profile; there were robust reductions in LDL cholesterol levels in all genotypes of familial hypercholesterolemia.
Journal ArticleDOI
Oral peanut immunotherapy in children with peanut anaphylaxis
Katharina Blumchen,Helen Ulbricht,U. Staden,Kerstin Dobberstein,John Beschorner,Lucila Camargo Lopes de Oliveira,Wayne G. Shreffler,Hugh A. Sampson,Bodo Niggemann,Ulrich Wahn,Kirsten Beyer +10 more
TL;DR: Long-term OIT appears to be safe and of some benefit in many patients with peanut allergy, with an increase in threshold levels and a reduction of peanut-specific T(H)2 cytokine production, the induction of tolerance may be feasible in some patients.
References
More filters
Journal ArticleDOI
Fatal and Near-Fatal Anaphylactic Reactions to Food in Children and Adolescents
TL;DR: Six children and adolescents who died of anaphylactic reactions to foods and seven others who nearly died and required intubation were identified and the failure to recognize the severity of these reactions and to administer epinephrine promptly increases the risk of a fatal outcome.
Journal ArticleDOI
Fatalities due to anaphylactic reactions to foods.
TL;DR: Fatal anaphylactic reactions to foods are continuing to occur, and better characterization might lead to better prevention, and peanuts and tree nuts accounted for more than 90% of the fatalities.
Journal ArticleDOI
Clinical features and severity grading of anaphylaxis
TL;DR: A simple grading system and definition of anaphylaxis has potential value for defining reaction severity in clinical practice and research settings and appears to be the major determinants of reaction severity.
Journal ArticleDOI
Symposium on the Definition and Management of Anaphylaxis: Summary report
Hugh A. Sampson,Anne Muñoz-Furlong,S. Allan Bock,Cara Schmitt,Robert Bass,Badrul A. Chowdhury,Wyatt W. Decker,Terence J. Furlong,Stephen J. Galli,David B.K. Golden,Rebecca S. Gruchalla,Allen D. Harlor,David L. Hepner,Marilyn Howarth,Allen P. Kaplan,Jerrold H. Levy,Lawrence M. Lewis,Phillip Lieberman,Dean D. Metcalfe,Ramon Murphy,Susan M. Pollart,Richard S. Pumphrey,Lanny J. Rosenwasser,F. Estelle R. Simons,Joseph P. Wood,Carlos A. Camargo +25 more
TL;DR: This dissertation aims to provide a history of medical marijuana use in the United States and Canada over a 40-year period from 1989 to 2002, with a focus on the period up to and including the year ending in 2002.
Journal ArticleDOI
Advances in H1-Antihistamines
TL;DR: There are clinically relevant differences among H1-antihistamines in their pharmacology and safety profiles in allergic rhinoconjunctivitis and chronic urticaria.